NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
 

Preliminary results: SHOP APOTHEKE EUROPE accelerates international expansion and further speeds up growth rate.

- First quarter company revenues increased to 64.3 million Euros compared to 41 million Euros a year earlier

- Rate of growth rose to 57% compared to 52% the previous quarter and 41 percent in FY 2016

- International revenues more than tripled to 16 million Euros

- Forecast for 2017 confirmed
 

Venlo, the Netherlands, April 18, 2017 - SHOP APOTHEKE EUROPE N.V., Europe's leading online OTC pharmacy (OTC = over the counter = non-prescription medications), has started the 2017 fiscal year dynamically, posting significant revenue growth. According to preliminary calculations, the company's first quarter revenues climbed to 64.3 million Euros compared to 41 million Euros during the same period the previous year. This corresponds to a 57% increase which represents a further acceleration of growth compared to the previous quarter (Q4/2016) when SHOP APOTHEKE EUROPE had increased its revenues by 52%. The growth rate for the 2016 fiscal year had been 41%.

The further enhanced growth is the result of the company's consistent acceleration of its international expansion, particularly the rapid integration of the online pharmacy FARMALINE acquired in September 2016. While first quarter revenues for Germany increased by 33% year-to-year from 35.6 million euros in Q1 2016 to 47.5 million euros in Q1 2017, revenues for the company's second core segment "International" more than tripled to 16 million Euros during the same timeframe (Q1 2016: 5 million Euros). The segment "Germany services," which includes webshop services, posted revenues of 0.8 million Euros excluding intra-company services (Q1 2016: 0.4 million Euros).

Based on the company's strong first quarter growth, the Management Board confirmed its forecast for the 2017 fiscal year, projecting a 45% to 55% percent increase in revenues primarily driven by the growth in international business. In line with the projected growth, the company's gross margin is expected to increase during the current fiscal year. Management also expects the company-level EBITDA margin to improve to -2% from -3%.

All figures included in this release are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish final first quarter results as scheduled on May 15, 2017.

 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is Continental Europe's leading online OTC pharmacy with a portfolio that focuses on OTC medication and pharmacy-related beauty and care products (BPC). The Company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to 1.8 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated EUR 177 million in revenues in the financial year of 2016. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices in Cologne, Düsseldorf, Paris and Tongeren, Belgium. The online pharmacy has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.

FINANCIAL CALENDAR 2017

CONFERENCES 2017

MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
E-Mail: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Phone: +31 77 850 6117
E-Mail: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This announcement does not constitute a public offer or an offer to subscribe to any securities in any jurisdiction. The offer was made exclusively on the basis of the company's securities prospectus that had been published in connection with the offer. The shares have already been sold.

This announcement contains forward-looking statements that relate to the future course of business and future financial performance, as well as future transactions or developments concerning SHOP APOTHEKE EUROPE. The bases of these statements are current expectations and assumptions of SHOP APOTHEKE EUROPE's management, of which a large number are outside SHOPE APOTHEKE EUROPE's sphere of influence. These statements are therefore subject to a variety of risks and uncertainties. If such risks and uncertainties occur, or if the underlying expectations do not materialize or the assumptions made are not correct, the actual events, both positive and negative, may differ materially from those events contained in the forward-looking statements. SHOP APOTHEKE EUROPE assumes no obligation to update these forward-looking statements or to correct them in the event of occurrences or developments other than those anticipated. Such updates or corrections are not intended.